Vincristine Sulfate

Vincristine Sulfate

Synonyms 22-oxo-vincaleukoblastine sulfate; Leuocristine sulfate (1:1); Vincrisul; VCR

CAS Number: 2068-78-2 Molecular Formula: C46H58N4O14S Molecular Weight: 923.044 g/mol

Beilstein Registry Number: 3924631 EC Number: 218-190-0 MDL Number: MFCD00084729

Configure Your Product:

SKU 02190687-CF
Price:
$84.50
In Stock
Request a quote
Description

Product Description

Vincristine Sulfate

Application Notes

Vincristine Sulfate is used to treat acute leukaemia, malignant lymphoma, Hodgkin′s disease, acute erythraemia, acute panmyelosis, breast cancer, Kaposi’s sarcoma and testicular cancer. It is widely used in cancer research. It is used to study multi-drug resistance. It is used to inhibit cell cycle progression at M-phase and to inhibit monoamine oxidase (MAO).

Usage Statement

Research Use Only (RUO). Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Key Applications

Antitumor agent||Treatment of acute leukaemia; malignant lymphoma; Hodgkin′s disease; acute erythraemia; acute panmyelosis; Breast cancer

Specifications
SKU 02190687-CF
Alternate Names 22-oxo-vincaleukoblastine sulfate; Leuocristine sulfate (1:1); Vincrisul; VCR
Application Notes Vincristine Sulfate is used to treat acute leukaemia, malignant lymphoma, Hodgkin′s disease, acute erythraemia, acute panmyelosis, breast cancer, Kaposi’s sarcoma and testicular cancer. It is widely used in cancer research. It is used to study multi-drug resistance. It is used to inhibit cell cycle progression at M-phase and to inhibit monoamine oxidase (MAO).
Beilstein Registry Number 3924631
Biochemical Physiological Actions Vincristine is a plant alkaloid that inhibits microtubule assembly by binding tubulin and inducing coiled spiral aggregate formation. It arrests cell cycle in G2/M-phase by blocking mitotic spindle formation. Vincristine triggers Raf-1 activation, phosphorylation of bcl-2-family proteins, induction of p53 expression, and apoptosis in several tumor cell lines. It inhibits VEGF production in leukemia cell lines. It is a substrate for Pgp and CYP3A4. MRP1 transports vincristine in an ATP- and GSH-dependent manner. Vincristine has some immunosuppressant effect. Vincristine may also interfere with amino acid, cyclic AMP, and glutathione metabolism, calmodulin-dependent Ca2+-transport, cellular respiration, and nucleic acid and lipid biosynthesis.
EC Number 218-190-0
Format powder
Hazard Statements H300-H341-H361fd
Applications Antitumor agent||Treatment of acute leukaemia; malignant lymphoma; Hodgkin′s disease; acute erythraemia; acute panmyelosis; Breast cancer
MDL # MFCD00084729
Melting Point 531° F approximately (NTP, 1992)
Molecular Formula C46H58N4O14S
Molecular Weight 923.044 g/mol
Physical Appearance White Powder
Product Families Description Vincristine sulfate
Product Overview Vincristine Sulfate
RTECS Number OH6340000
Safety Symbol GHS06, GHS08
Solubility greater than or equal to 10 mg/mL at 75° F (NTP, 1992)
Storage and Handling Store at +4 °C; desiccate; protect from light.
Usage Statement Research Use Only (RUO). Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.